您当前所在的位置:首页 > 产品中心 > 产品详细信息
166518-60-1 分子结构
点击图片或这里关闭

1-({[2,6-bis(propan-2-yl)phenoxy]sulfonyl}amino)-2-[2,4,6-tris(propan-2-yl)phenyl]ethan-1-one

ChemBase编号:72881
分子式:C29H43NO4S
平均质量:501.72102
单一同位素质量:501.29127986
SMILES和InChIs

SMILES:
c1c(cc(c(c1C(C)C)CC(=O)NS(=O)(=O)Oc1c(cccc1C(C)C)C(C)C)C(C)C)C(C)C
Canonical SMILES:
O=C(NS(=O)(=O)Oc1c(cccc1C(C)C)C(C)C)Cc1c(cc(cc1C(C)C)C(C)C)C(C)C
InChI:
InChI=1S/C29H43NO4S/c1-17(2)22-14-25(20(7)8)27(26(15-22)21(9)10)16-28(31)30-35(32,33)34-29-23(18(3)4)12-11-13-24(29)19(5)6/h11-15,17-21H,16H2,1-10H3,(H,30,31)
InChIKey:
PTQXTEKSNBVPQJ-UHFFFAOYSA-N

引用这个纪录

CBID:72881 http://www.chembase.cn/molecule-72881.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
1-({[2,6-bis(propan-2-yl)phenoxy]sulfonyl}amino)-2-[2,4,6-tris(propan-2-yl)phenyl]ethan-1-one
1-{[2,6-bis(propan-2-yl)phenoxysulfonyl]amino}-2-[2,4,6-tris(propan-2-yl)phenyl]ethan-1-one
IUPAC传统名
1-[(2,6-diisopropylphenoxysulfonyl)amino]-2-(2,4,6-triisopropylphenyl)ethanone
别名
CI-1011; PD 148515; [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester] sulfamic acid
Avasimibe
CI-1011
Avasimibe
CAS号
166518-60-1
MDL号
MFCD00934956
PubChem SID
162037802
PubChem CID
166558

数据来源

数据来源

所有数据来源 商品来源 非商品来源
数据来源 数据ID
PubChem 166558 external link

理论计算性质

理论计算性质

JChem
Acid pKa 2.9000666  质子受体
质子供体 LogD (pH = 5.5) 7.732911 
LogD (pH = 7.4) 7.724647  Log P 8.667485 
摩尔折射率 144.8079 cm3 极化性 56.883415 Å3
极化表面积 72.47 Å2 可自由旋转的化学键
里宾斯基五规则 false 

分子性质

分子性质

理化性质 安全信息 药理学性质 产品相关信息 生物活性(PubChem)
溶解度
DMSO: ≥40 mg/mL expand 查看数据来源
外观
white to tan powder expand 查看数据来源
保存条件
-20°C expand 查看数据来源
MSDS下载
下载链接 expand 查看数据来源
德国WGK号
3 expand 查看数据来源
保存温度
room temp expand 查看数据来源
作用靶点
ACAT expand 查看数据来源
纯度
≥98% (HPLC) expand 查看数据来源
成盐信息
Free Base expand 查看数据来源
Empirical Formula (Hill Notation)
C29H43NO4S expand 查看数据来源

详细说明

详细说明

Selleck Chemicals Selleck Chemicals Sigma Aldrich Sigma Aldrich
Selleck Chemicals -  S2187 external link
Research Area
Description Cardiovascular Disease
Biological Activity
Description Avasimibe inhibits ACAT and CYP2C9 with IC50 of 3.3 μM and 2.9 μM, respectively.
Targets

ACAT

CYP2C9

CYP1A2

CYP2C19

IC50

3.3 μM [1]

2.9 μM

13.9 μM

26.5 μM [5]

In Vitro Avasimibe at concentration of 1μg/mL causes reduction of Total cholesterol (TC) and Esterified cholesterol (EC) through inhibiting LDL binding and decreasing scavenger receptor numbers during foam cell formation in human monocyte-derived macrophages (HMMs). Avasimibe at concentration of 2μg/mL enhances cholesterol efflux from established HMM foam cells preincubating with 10μg/ml LDL. [1] Avasimibe inhibits Lipoprotein(a) accumulation in the culture media of primary monkey hepatocyte in a dose-dependent manner with 11.9% -31.3% inhibition, the change is mainly associated with decreased ApoA. [2] Avasimibe incubating at concentration of 10 nM, 1 μM, and 10 μM for 24 hours in HepG2 cells reduce ApoB secretion into media by 25%, 27%, and 43%, respectively. Avasimibe decreases ApoB secretion by enhanced intracellular degradation of ApoB rather than decreased synthesis of ApoB. [3] Avasimibe inhibits ACTC with IC50 of 3.3 μM in IC-21 macrophages with consideration of the total inhibitor concentration in the assay sample. [4] Avasimibe inhibits human P450 isoenzymes CYP2C9, CYP1A2 and CYP2C19 with IC50 of 2.9 μM, 13.9 μM and 26.5 μM, respectively. [5] Avasimibe inhibits ACAT-1 expression and cholesterol ester synthesis in glioma cell lines. Avasimibe inhibits the growth of the glioma cells by inducing cell cycle arrest and apoptosis due to caspase-8 and caspase-3 activation. [6]
In Vivo Avasimibe significantly reduces Lipoprotein(a) and total cholesterol levels in nine healthy male monkeys with a normal chow diet orally treated with CI-1011 at 30 mg/kg per day for 3 weeks, Lipoprotein(a) and total cholesterol levels reduce to 68 and 73% of control levels, respectively. Avasimibe decreases total cholesterol mainly due to reduction of low density lipoprotein (LDL). [2] Avasimibe decreases amyloid plaque load in the cortex and hippocampus and reduces the levels of insoluble Abeta40 and Abeta42 and C-terminal fragments of amyloid precursor protein (APP) in brain extracts in young human APP transgenic mice. Avasimibe reduces diffuse amyloid plaques by suppression of astrogliosis and enhanced microglial activation in aged human APP transgenic mice. [7]
Clinical Trials
Features
Combination Therapy
Description Avasimibe at concentration of 0.5 μM enhances atorvastatin caused reduction of esterified cholesterol content at concentration of 5 μM in THP-1 macrophages. [8]
Protocol
Kinase Assay [1]
P450 Inhibition Studies Pooled human liver microsomes (HLM) from at least 15 donors are used for all inhibition assays. For IC50 determinations, the substrate probes are used at their approximate in vitro Km values. All incubations are performed with 100 mM potassium phosphate buffer (pH 7.4) and 1 mM NADPH. For CYP1A2 inhibition study, incubations are performed in a total volume of 0.5 ml, in duplicates with 0.1 mg/ml HLM, 30 μM phenacetin, 1 mM NADPH, and in the presence of avasimibe (0, 0.3, 0.75, 1.5, 3, 7.5, 15, 30, and 40 μM in 50 mM) in a potassium phosphate buffer at pH 7.4. After preincubation at 37 °C for 7 min, NADPH is added to initiate the enzyme reaction. The reaction mixture is quenched with 500 μl of ice-cold 100 ng/ml paracetamol-D4/CH3CN after 25 min. The standards (4-acetamidophenol, singlet) and quality controls (triplicates for low, medium, and high) are prepared at room temperature. After mixing, 0.2 ml of the samples is transferred to another plate and submitted for LC/MS/MS analysis after centrifugation at 3000 rpm for 10 min. A Supelco Discovery Amide C16, 100 × 2.1 mm (5-μm particle size) column (Supelco, Bellefonte, PA) is used. The mobile phase is isocratic, 40:60 [acetonitrile/formic acid, 0.1% (v/v)] at 0.2 ml/min.
Animal Study [2]
Animal Models male cynomolgus monkeys
Formulation sterile 0.9% sodium chloride solution
Doses 30 mg/kg
Administration Orally at a single dose per day for 3 weeks
References
[1] Lee HT, et al. J Med Chem, 1996, 39(26), 5031-5034.
[2] Ramharack R, et al. Atherosclerosis, 1998, 136(1), 79-87.
[3] Wilcox LJ, et al. Arterioscler Thromb Vasc Biol, 1999, 19(4), 939-949.
[4] Rodriguez A, et al. Atherosclerosis, 2002, 161(1), 45-54.
[5] Castillo U, et al. FEMS Microbiol Lett, 2003, 224(2), 183-190.
[6] Bemlih S, et al. Cancer Biol Ther, 2010, 9(12), 1025-1032.
[7] Huttunen HJ, et al. J Neuropathol Exp Neurol, 2010, 69(8), 777-788.
[8] Llaverís G, et al. Eur J Pharmacol, 2002, 451(1), 11-17.
Sigma Aldrich -  PZ0190 external link
Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Biochem/physiol Actions
Avasimibe (CI-1011) is an orally bioavailable Acyl-CoA:Cholesterol O-Acyltransferase (ACAT) inhibitor. It was originally developed as an antilepic drug, and was shown to significantly reduce plasma total triglyceride and VLDL-cholesterol, but later clinical trials were disappointing. ACAT has also been investigated as a potential therapeutic target for Alzheimer′s disease. Recent studies have looked at the effects of avasimibe in reducing amyloid pathology by limiting generation and increasing clearance of diffusible amyloid-beta (Abeta).

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle